Silencing of aberrantly expressed
microRNAs (
miRNAs or miRs) has emerged as one of the strategies for molecular targeted
cancer therapeutics. In particular, miR-21 is an oncogenic
miRNA overexpressed in many
tumors, including
ovarian cancer. To achieve efficient administration of
anti-miR therapeutics, delivery systems are needed that can ensure local accumulation in the
tumor environment, low systemic toxicity, and reduced adverse side effects. In order to develop an improved
anti-miR therapeutic agent for the treatment of
ovarian cancer, a nanoformulation is engineered that leverages biodegradable porous
silicon nanoparticles (pSiNPs) encapsulating an anti-miR-21
locked nucleic acid payload and displaying a
tumor-homing
peptide for targeted distribution. Targeting efficacy, miR-21 silencing, and anticancer activity are optimized in vitro on a panel of
ovarian cancer cell lines, and a formulation of anti-miR-21 in a pSiNP displaying the targeting
peptide CGKRK is identified for in vivo evaluation. When this nanoparticulate agent is delivered to mice bearing
tumor xenografts, a substantial inhibition of
tumor growth is achieved through silencing of miR-21. This study presents the first successful application of
tumor-targeted
anti-miR porous
silicon nanoparticles for the treatment of
ovarian cancer in a mouse xenograft model.